Pioneering prescription digital therapeutics

Reversing insulin resistance with AI-driven lifestyle modification.

Get in touch
Pioneering prescription digital therapeutics - Vitadio
Class I medical device under MDR
ISO 27001 and GDPR compliant
Developed by healthcare professionals

Our purpose

Empowering people to restore their cardiometabolic health.

1 in 3 adults suffers from more than one chronic condition. We create digital therapies that treat the cause, not the symptoms. One habit at a time. Without side effects.

Empowering people to restore their cardiometabolic health - Vitadio
The first digital therapy for type 2 diabetes, covered by all statutory health insurers in Germany.

Robust DTx platform with a human touch

Personalized therapy - Vitadio

Personalised therapy

Building healthy habits via smart nudges and personalised goals. We combine evidence-based content and complex user data to provide daily engaging guidance.

AI-driven real-time feedback - Vitadio

AI-driven real-time feedback

Our proprietary AI model provides real-time diet feedback and recommendations. Just like a human dietitian but anywhere and anytime the user needs it.

Proactive human support - Vitadio

Proactive human support

Support and guidance whenever the user needs it. Whether it is sharing experiences with others in the in-app social network or proactive support of a personal dietitian.

Exceptional engagement rate proven by thousands of users

0% of users stay more than 3 months
0% of users log in every day (on par with Twitter)
0x higher adoption compared to face-to-face therapy

Clinically proven outcomes

The clinical effect of our digital therapeutics is comparable to modern antidiabetic drugs. We are committed to rigorous validation in clinical studies.

2.6x

more patients achieved the recommended level of HbA1c compared to the standard of care

70%

of patients report a significant
weight reduction

The biggest pharmaceutical players augment their pharmacotherapy with Vitadio

What are the benefits of combining medication with digital therapeutics?
Logo AstraZeneca
Logo Novo Nordisk
  • Achieving a superior reduction in HbA1c and body weight
  • Improving quality of life
  • Driving better adherence to treatment
  • Providing differentiation in the market

How it started

Our story began in 2019 when our 4 founders decided to innovate type 2 diabetes care and provide best-in-class therapy by combining the power of artificial intelligence and evidence-based medicine.

Today, Vitadio, with headquarters in Prague and Berlin, offers digital therapeutics for type 2 diabetes and prediabetes across three European countries, with ongoing expansion efforts.

Vitadio Founders
we're hiring.

Join our purpose-driven team that tackles the biggest challenges in healthcare.